secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0001847903-23-000182
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa presents ORX750 preclinical data; shows potential best-in-class profile for narcolepsy
--------------------------------------------------------------------------------

- ORX750 potently activates OX2R with EC50 of 0.11 nM and 9,800-fold selectivity over OX1R.
- Oral doses as low as 0.1 mg/kg achieved 100% wake time for ≥3 hours and suppressed cataplexy for ≥6 hours in mouse models.
- Effects on wake and cataplexy latency maintained for >14 days of dosing.
- Clinical proof-of-concept data planned for 2024; IND-enabling studies ongoing.
- Preclinical PK profile suggests high, early, and sustained brain exposure in multiple species.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000182/0001847903-23-000182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000182/cnta-20231025.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer